Your prediction
Syndax Pharmaceuticals Inc Stock
A loss of -1.150% shows a downward development for Syndax Pharmaceuticals Inc.
So far the community has only identified positive things for Syndax Pharmaceuticals Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Syndax Pharmaceuticals Inc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Syndax Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -1.150% | -0.571% | 20.000% | 34.884% | 41.463% | -23.009% | - |
| Pacira Pharmaceuticals | 1.900% | 4.902% | 4.902% | 14.439% | 15.676% | -49.528% | -53.275% |
| Rockwell Medical Inc. | -0.990% | -5.729% | -2.742% | -59.451% | -60.417% | -14.194% | -92.157% |
| Twist Bioscience Corp | -2.080% | -5.009% | -4.111% | -41.759% | -42.357% | 8.611% | -77.470% |
News
Syndax (SNDX) Q2 Revenue Jumps 986%
Syndax Pharmaceuticals (NASDAQ:SNDX), a biopharmaceutical company specializing in oncology therapeutics, reported its second-quarter 2025 earnings on August 4, 2025. The most notable news was its
